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Abstract 
Recently, employing radioligand displacement and functional coupling studies, we demonstrated 
that SB269,652 (N-[(1r,4r)-4-[2-(7-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-1H-
indole-2-carboxamide) interacts in an atypical manner with dopamine D3 receptor displaying a 
unique profile reminiscent of a negative allosteric ligand. Here, we characterized the binding of 
radiolabelled [
3
H]SB269,652 to human dopamine D3 receptor stably expressed in Chinese Hamster 
Ovary cells. Under saturating conditions, SB269,652 showed a KD value of ≈ 1 nM. Consistent 
with high selectivity for human dopamine D3 receptor, [
3
H]SB269,652 binding was undetectable in 
cells expressing human dopamine D1, D2L or D4 receptors and absent in synaptosomes from 
dopamine D3 receptor knockout vs. wild-type mice. In contrast to saturation binding experiments, 
the dissociation kinetics of [
3
H]SB269,652 from human dopamine D3 receptors initiated with an 
excess of unlabelled ligand were best fitted by a bi-exponential binding model. Supporting the 
kinetic data, competition experiments with haloperidol, S33084 (a dopamine D3 receptor 
antagonist) or dopamine, were best described by a two-site model. In co-transfection experiments 
binding of SB269,652 to dopamine D3 receptor was able to influence the functional coupling of 
dopamine D2 receptor, supporting the notion that SB269,652 is a negative allosteric modulator 
across receptor dimers. Hovever, because SB269,652 decreases the rate of [
3
H]nemonapride 
dissociation, the present data suggest that SB269,652 behaves as a bitopic antagonist at unoccupied 
dopamine D3 receptor, binding simultaneously to both orthosteric and allosteric sites, and as a pure 
negative allosteric modulator when receptors are occupied and it can solely bind to the allosteric 
site. 
Keywords  
Dopamine, receptor binding study, receptor dimerization 
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1. Introduction 
Dopamine D3 receptors are members of the dopamine D2-like family of G protein-coupled 
receptors (GPCRs) that signal via the Gαi class of GTP-binding proteins to inhibit adenylyl cyclase 
and activate diverse kinase signaling cascades (Sokoloff and Le Foll, 2017). They are critically 
involved in a number of physiological processes such as the control of cognition, mood and motor 
behaviour (Beaulieu and Gainetdinov, 2011). Accordingly, dopamine D3 receptors may be a target 
for the treatment of neuropsychiatric disorders and, due to their enrichment in mesolimbic 
dopaminergic projection areas, they are of particular interest for the potential control of 
schizophrenia (Gross and Drescher, 2012; Millan et al., 2016) and drug addiction (Heidbreder and 
Newman 2010; Joyce and Millan, 2005). 
Conventionally, and by analogy to dopamine D2 receptors, the design of dopamine D3 receptor 
ligands has focused on the orthosteric binding site (Pich and Collo, 2015). However, in recent years, 
allosteric modulation of GPCR activity has attracted interest as an alternative route towards the 
development of selective and well-tolerated drugs for use either alone or together with other classes 
of agent. An attractive feature of positive and negative allosteric modulators is their concentration-
response relationship, which plateaus, and permits the development of treatments with a broad 
therapeutic dose-range avoiding the risk of excessive activation or blockade of receptor-signalling: 
this underpins the interest in their clinical application either alone or as adjunctive treatments 
(Smith and Milligan, 2010; Hudson et al., 2013; Christopoulos, 2014).  
Recently, by employing a broad and complementary range of cellular approaches, we revealed that 
the novel tetrahydroisoquinoline derivative, SB269,652, behaves as an atypical antagonist at 
dopamine D3 and dopamine D2 receptors (Silvano et al., 2010). In particular, SB269,652 potently 
abolished the specific binding of [
3
H]nemanopride and [
3
H]spiperone to dopamine D3 receptors 
while only weakly and partially (by approximately 20-30%) inhibited the radioligand binding to 
dopamine D2 receptors. However, when [
3
H]nemanopride and [
3
H]spiperone were employed at 10-
fold higher concentrations, SB269,652, even at very high concentrations, could only sub-maximally 
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inhibit their specific binding at dopamine D3 receptor. Similarly, SB269,652 potently blocked 
dopamine D3 receptor-mediated activation of Gαi3, however, when concentrations of dopamine 
were increased 10-folds, from 1 μM to 10 μM, SB269,652 inhibited dopamine-induced stimulation 
of Gαi3 only submaximally, indicating, once more, that SB269,652 behaved also as a negative 
allosteric modulator. Furthermore, the binding kinetics of [
3
H]nemonapride and [
3
H]spiperone at 
dopamine D2 and dopamine D3 receptors were clearly modified in the presence of SB269,652 
compared with the two orthosteric antagonists, haloperidol and sulpiride. Taken together, these 
results strongly suggest that SB269,652 behaves as a negative allosteric modulator at dopamine D2 
and dopamine D3 receptors - the first to be identified. The allosteric nature of this compound was 
subsequently confirmed by Lane et al. (2014); Shonberg et al., (2015); Mistry et al. (2015) for 
dopamine D2 receptor and by Kumar et al. (2017), for dopamine D3 receptor, and now SB269,652 
has become a leading compound in the synthesis of new allosteric drugs (Rossi et al., 2017). 
In view of this interest in allosteric modulators of dopaminergic receptors and more specifically, 
SB269,652, in the present work, this compound was radiolabelled in order to characterize its 
putatively allosteric actions at recombinant human dopamine D3 receptor. 
 
2. Materials and methods  
2.1. Radiolabelled compounds. 
SB269,652 is a N-[(1r,4r)-4-[2-(7-cyano-1,2,3,4-tetrahydroisoquinolin-2- 
yl)ethyl]cyclohexyl]-1H-indole-2-carboxamide. It has two diastereoisomers due to the presence of a 
cyclohexane moiety in its structure; the trans diastereoisomer was used in this work and was 
radiolabelled with tritium to a specific activity of 26 Ci/mmol. SB269,652 was synthesized by G. 
Lavielle (Servier, Paris, France). [
3
H]Nemonapride (85.5 Ci/mmol) and N-[
3
H]methylscopolamine 
(83 Ci/mmol) were purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA). 
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2.2.  Construction of dopamine D3D110A mutant, and dopamine D3-trunk and dopamine 
D2-trunk receptor fragments.  
The human dopamine D3 receptor was used to make the dopamine D3D110A and the human 
dopamine D3-trunk receptor mutants. In the D3D110A construct, aspartate 110 in transmembrane 
region III was replaced by alanine. The dopamine D3-trunk receptor fragment was made by 
inserting a STOP codon into the dopamine D3 receptor after amino acid isoleucine 290 and by 
removing the C-terminal part of the intracellular loop 3 and transmembrane regions VI and VII. The 
dopamine D2-trunk receptor fragment was generated as described in (Scarselli et al., 2000). The 
plasmids were transiently transfected in COS-7 cells by the DEAE-dextran chloroquine method. 
 
2.3. Stably-transfected CHO-D3, CHO-D2L, CHO-D1 and CHO-M4 cell lines and transiently 
transfected COS-7 cells.  
CHO-D3-DHFR
-
 cells (from now on named CHO-D3) were provided by Pierre Sokoloff 
(Sokoloff et al., 1992). CHO-D2L and CHO-D1 cells were generated by transfecting the human 
dopamine D2L or human dopamine D1 receptors, respectively, in wild type CHO cells (Aloisi et al., 
2011). CHO-hM4 (human muscarinic M4 receptor) cells were prepared as described previously in 
Maggio et al., 1995. COS-7 cells were used for transient transfections. Briefly, cells were seeded at 
a density of 5 x 10
5
 per 100-mm dish and 24 h later incubated with the DEAE-dextran chloroquine 
transfection reagent and with the respective plasmids as indicated for each experiment (Picchietti et 
al., 2009). The total amount of DNA used for each transfection was 4 mg (2 mg for each plasmid in 
co-transfection, unless otherwise specified. 
 
2.4. Evaluation of the affinities of SB269,652 at human dopamine D3 receptor, human 
dopamine D2L receptor, and human dopamine D2S receptor and at other classes of binding 
site.  
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SB269,652 affinities at various classes of dopaminergic receptors and other sites were 
determined using conventional procedures. All protocols used for determination of affinities of 
SB269,652 at the multiple classes of cloned receptors have been documented previously (Millan et 
al., 2008). The cell lines and radioligands used for determination of affinities are summarized in 
Table 4. 
 
2.5. Membrane preparation and binding assays.  
Confluent plates were washed twice with cold 0.9 % NaCl solution and lysed in ice-cold 
hypotonic buffer (1 mM Na-HEPES and 2 mM EDTA). After 20 min in ice, the cells were scraped 
off the plate and centrifuged at 35,000 g for 20 min. The lysed cell pellet was homogenized with 
Polytron homogenizer in the binding assay buffer (50 mM TRIS-HCl pH 7.4, 155 mM NaCl and 
0.01 mg/ml bovine serum albumin). Equilibrium binding experiments of [
3
H]SB269,652 and 
[
3
H]nemonapride to cells membranes were carried out at 30°C for 3 h in a final volume of 1 ml. The 
bound ligand was separated from the unbound ligand using glass-fibre filters (Whatmann, GF/B) 
with a Brandel Cell Harvester, and the filters were counted with a scintillation β-counter. 
Nonspecific binding was calculated in the presence of 2 mM dopamine. To calculate the 
dissociation rate constants (Koff) 20 ml of membranes were loaded with 5 nM [
3
H]SB269,652 for 2 h 
at 30°C and then diluted 100 times in presence of excess haloperidol (100 nM) or dopamine (1 
mM). To calculate the apparent association rate constant (Kobb), [
3
H]SB269,652 was used at a 
concentration of 1.6 nM. Binding to native dopaminergic receptors was performed using 
conventional procedures in male Wistar rats, 45 days old (Harlan, Italy) and in 90 days old, male, 
wild-type and dopamine D3 receptor (D3-/-) knockout C57Black mice. Experiments were performed 
following CEE procedures (directive/n.86/609) for the Care and Use of Laboratory Animals. 
Briefly, brain regions were dissected at 4
°
C and synaptosomal pellets (P2) fractions prepared as 
previously reported (Di Cara et al., 2011). The synaptosomal pellet was homogenized with a 
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Polytron homogenizer in the binding assay buffer, centrifuged and washed twice at 35,000 g for 20 
min. Membrane suspensions were used for binding studies. 
 
2.6. Adenylyl cyclase (AC) assays 
Twenty-four h after transfection, cells were transferred into 24-well plates and cultured for 
additional 24 h before running the adenylyl cyclase assays. In brief, the cells were incubated in 
fresh media for 2 h (0.25 ml/well) in the presence of 5 μCi/ml [
3
H]adenine. The media was then 
replaced with 0.5 ml/well of Dulbecco’s modified Eagle’s medium containing 20 mM HEPES, pH 
7.4, 0.1 mg bovine serum albumin, and the phosphodiesterase inhibitors, 1-methyl-3-
isobutylxanthine (0.5 mM) and RO-20-1724 (0.5 mM). 
AC activity was stimulated by addition of 10 μM forskolin in the presence or absence of quinpirole. 
The antagonist SB269,652 or SB277,011A were added 20 min before the agonists. 
After 10 min incubation at 30°C, the medium was removed and the reaction terminated with 
perchloric acid containing 0.1 mM unlabelled cAMP. The acid was then neutralized with KOH. The 
amount of [
3
H]cAMP produced was determined by a two-step column separation procedure, as 
described previously in  Maggio et al., 2003. 
 
2.7. Fitting and analysis of data. 
KD and Bmax values of [
3
H]SB269,652 and [
3
H]nemonapride, and Bmax values of 
[
3
H]methylscopolamine, were calculated in direct saturation experiments, whereas inhibitory 
concentration (IC)50 values were calculated in competition binding experiments, that were fitted by 
a one or two sites binding models. Kinetics experiments were fitted to mono or bi-exponential 
binding models. The Kon was calculated by the formula [Kon = (Kobb - Koff)/L], where L is the 
concentration of the radioligand. Statistics were run with iterative, non-linear least-squares 
regression analysis using OriginPro 7.5 software (OriginLab Corporation, Northampton, MA, 
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USA). The goodness-of-fit of one or two sites models in equilibrium and kinetics binding 
experiments was compared using F-tests with significance set at P < 0.05. 
 
3. Results 
3.1. Saturation binding experiments of [3H]SB269,652 and [3H]nemonapride in CHO cell 
membranes expressing dopamine D3 receptor.  
Binding of [
3
H]SB269,652 to CHO-D3 membranes was saturable with a KD of 0.983 ± 0.067 
nM (Fig. 1A) and a Hill coefficient not significantly different from 1 (1.106 ± 0.051). The mean 
Bmax calculated in three independent experiments was 5,204 ± 138 fmol/mg of protein (about 1.2 x 
10
6
 receptor/cell). In parallel experiments, [
3
H]nemonapride gave a similar Bmax value of 5,456 ± 
120 fmol/mg of protein (Table 1). 
 
3.2. Competition binding experiments with [3H]SB269,652 in stable transfected CHO-D3 
cells.  
As shown in Fig. 1B, [
3
H]SB269,652 competition binding curves with the high selective 
dopamine D3 receptor antagonist S33084 were best fitted with a two site binding model (F2,42 = 
38.19 →  P < 0.0001). On average, 43.6% of the sites had an IC50 of 0.271 ± 0.057 nM while the 
remaining sites had an IC50 of 44.48 ± 26.36 nM (Table 2). Data from competition binding 
experiments with haloperidol (Fig. 1C), were also best fitted with a two sites binding model (F2,39 = 
10.09 →  P = 0.0003), with approximately, 43.7% of the sites showing an IC50 of 3.401 ± 1.675 nM 
and the remaining sites an IC50 of 150.9 ± 57.43 nM (Table 2). Competition binding experiments 
with the agonist dopamine, were again best fitted with a two sites binding model (F2,30 = 8.13 →  P 
= 0.0015) (Fig. 1D). On average, 51.4% of the binding sites had an IC50 of 0.544 ± 0.195 µM while 
the remaining sites had an IC50 of 10.69 ± 9.387 µM (Table 2). 
 
3.3. Kinetic binding experiments of [3H]SB269,652 in stable transfected CHO-D3 cells.    
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 Dissociation kinetics of [
3
H]SB269,652 from CHO-D3 cell membranes, performed by 
dilution were best fitted with a one-phase exponential decay model that resulted in a Koff value 
(expressed in min
-1
) of 0.03 ± 0.002 (Table 3 and Fig. 2A). Conversely, dissociation kinetics 
performed by dilution and addition of an excess of haloperidol or dopamine were best fitted by a 
two-phases exponential decay model (F2,27 = 14.06 →  P < 0.0001 and F2,27 = 33.43 →  P < 0.0001, 
respectively) (Fig. 2B and C) with Koff values of fast and low kinetics of 0.241 ± 0.094 and 0.024 ± 
0.001 for haloperidol and 0.416 ± 0.089 and 0.256 ± 0.003 for dopamine, respectively (Table 3). In 
the presence of dopamine, fast dissociation of [
3
H]SB269,652 accounts for 41% of the bound 
receptors, while with haloperidol this fraction dropped to 20% (Table 3). Interestingly, dissociation 
kinetics performed in the presence of an excess of cold ligands resulted in association kinetics that 
were best fitted by a two-phase exponential growth function (Fig. 2D). The two apparent 
association rate constants in the presence of 1.6 nM [
3
H]SB269,652 were: Kobb1 = 0.553 ± 0.407 
and Kobb2 = 0.037 ± 0.007 min
-1
 (Table 3). Notably, the fast association rate constant accounted for 
24.16% of the saturated receptors. 
 
3.4. [3H]SB269,652 binding to dopamine D3D110A receptor mutant, to co-transfected 
dopamine D3D110A/D3-trunk receptor and to co-transfected dopamine D3D110A/D2-trunk 
receptor.  
In this set of experiments, we tested whether aspartate 110 in the third transmembrane 
region of dopamine D3 receptor was important for [
3
H]SB269,652 binding, inasmuch this type of 
mutation in the analogous residue (aspartate 114) of dopamine D2 receptor leads to a total loss of 
both agonist and antagonist binding (Sukalovic et al., 2015). As shown in Table 2, [
3
H]SB269,652 
(up to 10 nM) did not bind to dopamine D3D110A receptor mutant expressed in COS-7 cells. 
Analogous results were obtained with [
3
H]nemonapride. In order to exclude that the lack of binding 
to radioligands was due to incorrect folding and expression of dopamine D3D110A receptor mutant 
on the plasma membrane, we coexpressed the dopamine D3D110A receptor mutant with a receptor 
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fragment containing the first five transmembrane regions of dopamine D3 receptor (dopamine D3-
trunk receptor), and bearing the correct aspartate residue 110 in the third transmembrane region. As 
observed previously (Scarselli et al., 2003), if the dopamine D3D110A receptor mutant is correctly 
expressed on the membrane, the truncated fragment should rescue the binding to the radioligands. 
Even though only of modest efficiency, the binding of [
3
H]SB269,652 and [
3
H]nemonapride was 
indeed rescued when the dopamine D3D110A receptor mutant was co-transfected with the 
dopamine D3-trunk receptor fragment (Table 1). Conversely, only binding to [
3
H]nemonapride was 
rescued when dopamine D3D110A receptor mutant was co-transfected with the analogous truncated 
fragment derived from the dopamine D2 receptor (dopamine D2-trunk receptor). This shows that the 
chimeric, reconstituted dopamine D2/D3 receptor has low affinity for [
3
H]SB269,652 (Table 1). 
 
3.5. Binding of [3H]SB269,652 at other classes of dopamine receptor. 
 [
3
H]SB269,652 up to 10 nM did not bind to membranes generated from CHO-hD2L and 
CHO-hD1 cells nor it did bind to COS-7 cells transiently transfected with the human dopamine D4 
receptor (Table 1). Hence, it interacted specifically and only with recombinant dopamine D3 
receptor. 
 
3.6. Binding of [3H]SB269,652 to membranes from rat and mouse striatal synaptosomes. 
The affinity of [
3
H]SB269,652 was tested in membranes from synaptosomes prepared from 
rat and mouse striatum. The maximal binding capacity of [
3
H]SB269,652 in rat synaptosome 
membranes was 61.2 ± 11.3 fmol/mg protein. The KD, 421.7 ± 66.5 pM, was highly correlated with 
that obtained with cloned human dopamine D3 receptor. In order to verify whether this binding was 
specific to dopamine D3 receptor, parallel binding experiments were performed in synaptosomes of 
wild type and knockout dopamine D3 receptor (D3-/-) mice. These experiments showed that 
[
3
H]SB269,652 was able to bind to the synaptosomes from wild type mice with a Bmax of 71.1 ± 
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8.37 fmol/mg protein and a KD of 471.7 ± 112.9 pM (Fig. 3), whereas no binding was detected in 
synaptosomes from dopamine D3 receptor (D3-/-) KO mice. 
 
3.7. Binding affinity of SB269,652 to multiple GPCRs. 
Interestingly, [
3
H]SB269,652 displayed some specific binding also for the hM4 muscarinic 
receptor. In particular, at a radioligand concentration of 10 nM of [
3
H]SB269,652, a specific 
binding of 89.5 ± 13.7 fmol/mg was detected using CHO-hM4 cell membranes, accounting for 
nearly 16% of the Bmax calculated with the specific muscarinic antagonist N-
[
3
H]methylscopolamine (Table 1). No specific binding was detected on the other four classes of 
muscarinic receptor (data not shown). In view of this observation, we tested the affinity of cold 
SB269,652 for diverse classes of GPCR in comparison to hM4 and other subtypes of muscarinic 
receptor. As shown in Table 4, SB269,652 binds with high affinity to dopamine D3 receptor and 
displayed lower affinity at dopamine D2 receptors, yet it also revealed significant affinity for 
muscarinic hM2 and hM4 receptors, displaying IC50 values of 213 nM and 60.2 nM, respectively. 
These data are in line with those outlined above attained with the radiolabelled [
3
H]SB269,652 at 
hM4 receptors. 
 
3.8. Influence of SB269,652 and SB277,011A upon quinpirole-induced inhibition of forskolin-
stimulated ACVI activity at co-transfected dopamine D2/D3 receptor. 
 In order to address the effect of SB269,652 on dimeric dopamine D3 receptor, we co-
transfected dopamine D3 and D2 receptors in COS-7 cells. Significantly, these two receptors have 
been shown to interact with each other and to form heterodimers (Scarselli et al., 2001; Pou et al., 
2012). The activity of these two receptors can be easily distinguished in functional assays, as 
quinpirole inhibits forskolin mediated stimulation of ACVI only in COS-7 cells that co-express the 
dopamine D2 receptor and the ACVI, whereas it has no effect in COS-7 cells co-transfected with the 
dopamine D3 receptor and the ACVI (Fig. 4A). In COS-7 cells co-expressing both dopamine D2 and 
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dopamine D3 receptors and ACVI, the inhibitory effect of quinpirole on forskolin mediated 
activation of ACVI increased by four-fold in potency (Fig. 4A). 
The effect of SB269,652 on the ability of quinpirole to inhibit ACVI activity was tested on COS-7 
cells transfected with either dopamine D2 receptor alone, or co-transfected with dopamine D2 and 
dopamine D3 receptors. We observed that SB269,652 inhibited with very low potency and efficacy 
the action of quinpirole in dopamine D2 receptor transfected cells (Fig. 4B), whereas it was 
markedly more efficacious and potent at COS-7 cells co-expressing both dopamine D2 and 
dopamine D3 receptors (Fig. 4B). Importantly, even though there was an increase in the ability of 
SB269,652 to counter the actions of quinpirole in co-transfected dopamine D2/D3 receptor COS-7 
cells, the inhibition was only partial and reached a plateau, the competitive antagonist SB277,011A, 
completely reversed the influence of quinpirole on forskolin-stimulated ACVI activity, both in 
dopamine D2 receptor and in cotransfected dopamine D2/D3 receptor cells (Fig. 4C). SB277,011A 
was likewise more potent at cotransfected dopamine D2/D3 receptor cells. 
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4. Discussion 
In previous work we showed that SB269,652 displayed an atypical and allosteric-like pattern of 
interaction at dopamine D3 receptor and, less potently, at dopamine D2 receptor. The present study 
extends these observations in demonstrating that radiolabelled [
3
H]SB269,652 manifests high 
affinity, saturable, reversible and specific binding to recombinant human dopamine D3 receptor, and 
it shows likewise an unusual and distinctive binding profile consistent with a predominantly 
allosteric type of interaction.  
Whereas [
3
H]SB269,652 showed a strong interaction with the human dopamine D3 receptor, by 
displaying a Bmax very similar to that of the prototypical radiolabel, [
3
H]nemonapride (about 5 
pmol/mg), the compound was not able to bind to the human dopamine D1, dopamine D2 and 
dopamine D4 receptors underlying the specificity of its interaction for dopamine D3 receptor. The 
specific recognition of dopamine D3 vs. dopamine D2 receptors extended to native populations. 
Thus, [
3
H]SB269,652 bound to dopamine D3 receptor sites in synaptosomal preparations of the 
striatum from wild type mice, with an affinity comparable to that observed for cloned human 
dopamine D3 receptor, whereas binding was no detected in synaptosomes from dopamine D3 
receptor knockout mice. 
In saturation binding experiments, [
3
H]SB269,652 recognized an apparently homogeneous 
population of binding sites whereas, in kinetic experiments, the pattern of results was more 
complex. Thus, when [
3
H]SB269,652 dissociation was initiated by dilution, it revealed a binding 
behaviour consistent with a one binding site model. However, when [
3
H]SB269,652 dissociation 
was triggered by dilution and the addition of excess of the ligands, dopamine and haloperidol, a 
two-ligand binding site model best described its behaviour. These observations are reminiscent of 
those acquired with other radioligands - including those that do not necessarily act via an allosteric 
mechanism. For example, the opioid antagonist, [
3
H]naloxone benzoylhydrazone, binds to a single 
population of m-opioid receptors in saturation binding experiments whereas kinetic studies reveal a 
biphasic dissociation (Brown and Pasternak, 1998). Similar results have been published for the 
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muscarinic receptor antagonists, N-[
3
H]methylscopolamine and [
3
H]quinuclidinyl benzilate. In 
equilibrium binding experiments, these compounds bound to homogenous population of receptors 
yet, in kinetic experiments, the unlabelled ligands generated biphasic dissociation curves (Jakubík et 
al., 2000; Novi et al., 2003). This notion is also underlined by May et al. (2011) in work with 
adenosine A1 and A3 receptors, which demonstrated that the dissociation rate constants of the 
fluorescent agonist ABA-X-BY630 markedly increased in the presence of orthosteric agonists or 
antagonists. Moreover, these authors proposed an innovative method for detecting cooperative 
interactions amongst two topographically distinct binding sites based on the dissociation kinetics of 
a tracer ligand in the absence vs presence of an additional, cold ligand. Accordingly, for the present 
studies with [
3
H]SB269,652, an acceleration of its dissociation from dopamine D3 receptor in the 
presence of the orthosteric antagonist, haloperidol, or the agonist, dopamine would be consistent 
with a negative type of cooperativity between the radioligand on one hand and the cold ligand on 
the other. Taken together, these observations underpin the importance of performing kinetic studies 
with competing cold ligands to unveil otherwise-hidden, multiple sites or affinity states for a 
radioligand. 
In line with the kinetic experiments discussed above, competition binding isotherms with 
haloperidol, the highly selective dopamine D3 receptor antagonist S33084 (Cussac et al., 2000; 
Millan et al., 2000a, 2000b) and dopamine were in each case consistent with two populations of 
binding sites. Taken together these competition binding and kinetic data suggest that 
[
3
H]SB269,652 recognizes either multiple sites or multiple affinity states of the dopamine D3 
receptor. 
The conserved aspartate residue in transmembrane region 3 of amine receptors plays a pivotal role 
in the docking of ligands to the orthosteric binding site (Vaidehi et al., 2014). Dopamine D2 
receptors mutated at this residue lose the ability to bind orthosteric agonists and antagonists. An 
analogous mutation in the dopamine D3 receptor, dopamine D3D110A receptor mutant, prevented 
the binding of both [
3
H]SB269,652 and [
3
H]nemonapride. These results might in theory be 
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explained either by a lack of ability of the mutant receptor to bind these radioligands or by the lack 
of its expression at the plasma membrane. This issue was addressed by complementing the 
dopamine D3D110A receptor mutant with truncated mutants of dopamine D3 or dopamine D2 
receptors this approach mirrors a previous work, in which, the ligand-binding and functional 
properties of truncated receptors were rescued by co-expressing complementary non-functional 
GPCR fragments (Scarselli et al., 2000, 2003). In particular we found that the binding of both 
[
3
H]SB269,652 and [
3
H]nemonapride was restored when dopamine D3D110A receptor mutant was 
co-transfected with the dopamine D3-trunk receptor fragment. The fragment consists of the first 5 
transmembrane regions of the dopamine D3 receptor and by interacting with the dopamine 
D3D110A receptor mutant recreates a wild-type orthosteric binding site. [
3
H]nemonapride binding 
was likely restored in cells co-transfected with dopamine D3D110A receptor mutant and dopamine 
D2-trunk receptor mutant, whereas [
3
H]SB269,652 showed no binding, which is consistent with the 
high selectivity of SB269,652 for dopamine D3 receptor. These results underpin the concept that 
high affinity binding of [
3
H]SB269,652 to dopamine D3 receptor depends on the presence of an 
intact orthosteric binding site. 
Binding of [
3
H]SB269,652, at least in part, to the orthosteric site of the dopamine D3 receptor raises 
the issue of how this compound exerts its allosteric properties. One intriguing explanation may be 
found in the now broadly-accepted concept of GPCR homo- hetero- and higher order 
oligomerisation (Maggio et al., 2007; Scarselli et al., 2013, 2016; Shivanandan et al., 2014), which 
has been well-documented for dopamine D3 receptor (Marsango et al., 2015, 2017; Pou et al., 
2012). Dimerization can lead to crosstalk between protomers resulting in a cooperative pattern of 
ligand binding between them (Smith and Milligan, 2010). 
As mentioned above, dopamine D3 receptor form homo- (Karpa et al., 2000; Marsango et al., 2015; 
Nimchinsky et al., 1997; Pou et al., 2012) and heteromers (Fiorentini et al., 2010; Maggio and 
Millan, 2010; Maggio et al., 2015; Scarselli et al., 2001; Pou et al., 2012) in transfected cells as well 
as in native tissues. Clearly then, the formation of dopamine D3 receptor homomers could account 
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for the kind of binding behaviour observed with [
3
H]SB269,652 in kinetic and competition 
experiments. That is, [
3
H]SB269,652 likely binds to the orthosteric site of one protomer and 
allosterically modify the binding of ligand to the other protomer.  
To test this idea, we co-transfected dopamine D3 and dopamine D2 receptors inasmuch they have 
been shown to form heteromers (Scarselli et al., 2001; Pou et al., 2012), and can easily be 
distinguished in functional assays. In particular, when SB269,652 was tested at dopamine D2 
receptor alone, a modest reduction of quinpirole-induced inhibition of forskolin-stimulated ACVI 
activity was achieved at the higher concentrations of the drug. Conversely, when the dopamine D3 
receptor was co-transfected with dopamine D2 receptor a much stronger inhibition and an increase in 
potency was obtained with SB269,652, even though the inhibition reached a plateau. As quinpirole 
did not have any effect on dopamine D3 receptor alone, the data on co-transfected dopamine D3 and 
dopamine D2 receptors imply that SB269,652 binds to the dopamine D3 receptor to inhibits the 
dopamine D2 receptor via the dimer. Remarkably, a shift in potency was also observed with 
SB277,011A suggesting that mechanisms of cross inhibition can be relevant for other antagonists, 
potentially pure orthosteric ligands. 
This potential mechanism of action is supported by the work of Lane et al. (2014) on dopamine D2 
receptor. They proposed that SB269,652 acts as a bitopic ligand composed of two bridged 
pharmacophores that simultaneously bind to the orthosteric and allosteric sites of the same receptor 
protomer. Importantly, they fragmented SB269,652 into two pharmacophores: 1), the 7-cyano-
tetrahydroisoquinoline (7CN-THIQ) moiety that contains the tertiary amine, the part of the 
molecule that is important for the interaction with the conserved aspartic acid of the amine receptors 
in the orthosteric site and 2), the indole-2-carboxamide moiety that binds to an allosteric site of the 
dopamine D2 receptor in a non-competitive manner (Fig. 4). Furthermore, Shonberg et al. (2015) 
focusing on the three main chemical constituents of SB269,652 (Fig. 4), found that: a) the 7CN-
THIQ binding to the orthosteric site of dopamine D2 receptor is important for the orientation and 
binding of the indolcarboxamide to the allosteric site, and even subtle modifications of 7CN-THIQ 
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affect the functional affinity and negative allosteric cooperativity of the molecule; b) the indole-2-
carboxamide moiety of SB269,652 is important for its allosteric effect: SB269,652 analogues where 
indolic NH groups are substituted with others that are unable to generate hydrogen bonds lose the 
ability to allosterically interact with the receptor; c) linker length is critical for the allosteric effect 
of SB269,652 analogues. Lane et al. (2014) proposed that the binding of SB269,652 to one 
protomer of a dopamine D2 receptor dimer changes its binding properties at the orthosteric site of 
the other promoter of the dimer. According to this concept, SB269,652 behaves as a competitive 
antagonist at receptor monomers yet as a negative allosteric modulator across receptor dimers.  
This hypothesis – that seems to apply to dopamine D3 receptor - is supported by the above-
discussed data with the dopamine D3D110A receptor mutant, which lacks the aspartic acid in the 
orthosteric site crucial for binding of the tertiary amine in the 7CN-THIQ moiety of [
3
H]SB269,652. 
Moreover, in a previous study using chimeric dopamine D2/D3 receptor (Silvano et al., 2010), we 
showed that the extracellular loop II of the dopamine D3 receptor plays a pivotal role in binding 
SB269,652, which further supports the concept that this loop could bind the indole-2-carboxamide 
fragment of this compound. 
While this hypothesis is compelling, it does not necessarily account for all the results generated 
with SB269,652 at dopamine D3 receptor. Thus, we previously demonstrated that SB269,652 does 
not behave as a classic negative allosteric modulator: at high concentrations, in fact, it reduces 
radioligand dissociation rate constants at dopamine D2 and dopamine D3 receptors (Silvano et al., 
2010). Conversely, as shown herein, dopamine and haloperidol accelerated the dissociation of a 
fraction of [
3
H]SB269,652 from CHO-D3 cell membranes. The most parsimonious explanation to 
reconcile these apparently contrasting results would be that SB269,652 binds in two ways: when the 
orthosteric site is occupied by a ligand, SB269,652 would still be able to physically interact with the 
monomer through the receptor allosteric site and it would physically occlude the orthosteric site so 
that competitive antagonists would be unable to readily leave (or enter) the orthosteric site (Fig. 
5A). The lack of binding of [
3
H]SB269,652 to the dopamine D3D110A receptor mutant, in which 
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the bitopic interaction of the radioligand is prevented, could be explained by the much lower 
affinity of the radioligand bound to the sole allosteric site. On the other hand, when the receptor is 
unoccupied, SB269,652 would bind as a bitopic ligand to both orthosteric and allosteric binding 
sites of a single dopamine D3 receptor protomer, and orthosteric ligands would increase its 
dissociation by binding to the sibling protomer in the corresponding dimer (Fig. 5B). The allosteric 
properties of SB269,652 would then strictly depend on the ligand bound to the sibling protomer. In 
this context, the recognition of a single population of binding sites in saturation binding 
experiments and in studies of dissociation kinetic started by dilution, suggest that when SB269,652 
binds to one protomer in a dimer, it does not alter the binding of molecules of SB269,652 to the 
other protomer. A similar mechanism of binding and allostery has been described for the antagonist 
methoctramine at muscarinic M2 receptors (Jakubík et al., 2014). 
Intriguingly, despite high selectivity for human dopamine D3 receptor over other classes of 
dopamine receptors (see above), [
3
H]SB269,652 was found to bind membranes prepared from CHO 
cells expressing human muscarinic M4 receptor. In addition, in a broader screen (competition 
experiments) of GPCRs, despite a lack of interaction with multiple subtypes of monoaminergic 
receptor, cold SB269,652 revealed significant affinity for muscarinic M4 receptor and, albeit less 
potently, muscarinic M2 receptor. It would be interesting to determine the functional properties of 
SB269,652 at muscarinic receptors and to determine whether it behaves as an allosteric modulator 
and/or as an orthosteric ligand. While the interaction of SB269,652 suggests caution in its use as a 
cold ligand to probe the function of dopamine D3 receptor in vivo, the loss of [
3
H]SB269,652 
binding in dopamine D3 receptor knockout mice nonetheless underscores its interest as a radioligand 
for their characterisation at appropriately low concentrations and it could even become a candidate 
for probing dopamine D3 receptor occupancy by techniques such as Positron Emission 
Tomography. 
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Tables 
Table 1. Bmax values of [
3
H]SB269,652, [
3
H]Nemonapride and [
3
H]SCH23390 for wild type and 
dopamine receptor mutants stably and transiently expressed in CHO and COS-7 cells. Bmax values 
of N-[
3
H]metylscopolamine for the wild type muscarinic M4 receptor expressed in CHO cells.  
 
Receptor [
3
H]SB269,652 
(Bmax fmol/mg) 
[
3
H]Nemonapride 
(Bmax fmol/mg) 
[
3
H]SCH23390 
(Bmax fmol/mg) 
CHO-D3 5,204 ± 138 (3) 5,456 ± 120 (3)  
CHO-D2L N.D. (4) 3312 ± 227 (3)  
CHO-D1 N.D. (3)  1739 ± 273 (3) 
COS-7 – D4 N.D. (4) 902 ± 130 (3)  
COS-7 – D3D110A N.D. (7) N.D. (4)  
COS-7 – D3-trunk N.D. (2) N.D. (2)  
COS-7 – D2-trunk N.D. (2) N.D. (2)  
COS-7 – D3D110A + D3-trunk 71.3 ± 13.4 (4) 87.5 ± 11.7 (4)  
COS-7 – D3D110A + D2-trunk N.D. (4) 63.4 ± 7.91 (4)  
CHO-M4 89.5 ± 13.7
a
 (3)  [
3
H]NMS (Bmax fmol/mg) = 571 ± 22.3  
a
This value represent the amount of specific [
3
H]SB269,652 binding at a concentration of 10 nM. 
Next to this value is reported the Bmax of CHO-M4 cells calculated with [
3
H]NMS. Positive values 
represent the mean ± S.E.M. of three or four replicates. The number of experiments per condition is 
shown in round brackets.  N.D. = not detectable binding; [
3
H]NMS = N-[
3
H]methylscopolamine 
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Table 2. Binding parameters of inhibition isotherm of [
3
H]SB269,652 binding to CHO-D3 cell 
membranes. Values are expressed as means ± S.E.M. of three experiments. Competition curves 
were analyzed by a non-linear regression according to models assuming a single or a double class of 
binding sites. The best fit of two sites as compared to one site model was evaluated by F-test, 
utilizing normalized data from three experiments. 
 
Radioligand  [
3
H]SB269,652 
S33084 IC501 [nM] 
S33084 IC502 [nM] 
Bmax1 % = 100 - Bmax2 % 
Bmax2 % 
Hill Coefficient 
F2,42 = 38.19 →  P < 0.001 
0.27 ± 0.06 
44.5 ± 26.4 
43.6 
56.4 ± 4.69 
0.58 ± 0.06 
 
Haloperidol IC501 [nM] 
Haloperidol IC502 [nM] 
Bmax1 % = 100 - Bmax2 % 
Bmax2 % 
Hill Coefficient (one site) 
F2,39 = 10.09 →  P < 0.001 
3.4 ± 1.68 
151 ± 57.4 
43.7 
56.4 ± 9.15 
0.64 ± 0.06 
 
Dopamine IC501 [µM] 
Dopamine IC502 [µM] 
Bmax1 % = 100 - Bmax2 % 
Bmax2 % 
Hill Coefficient (one site) 
F2,30 = 8.13 →  P < 0.01 
0.55 ± 0.2 
10,7 ± 9,39 
51.4 
48.6 ± 14.5 
0.78 ± 0.05 
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Table 3. Binding parameters of [
3
H]SB269,652 kinetics at CHO-D3 cell membranes. Values are 
expressed as means ± S.E.M. of three experiments. Association and dissociation time courses were 
best fitted by a non-linear regression analysis according to a biexponential model. The best fit of the 
biexponential as compared to the monoexponential model was evaluated by F-test, utilizing 
normalized data from three experiments. 
 
Kinetic parameters of [
3
H]SB269,652 on CHO-D3 cells  Binding (%) 
Koff [min
-1
] (dilution) 0.03 ± 0.002  
Koff1 [min
-1
] (dilution + excess haloperidol) 
Koff2 [min
-1
] (dilution + excess haloperidol) 
F2,27 = 14.06 →  P < 0.0001 
0.24 ± 0.09 
0.02 ± 0.001 
19.7 
80.3 
Koff1 [min
-1
] (dilution + excess dopamine) 
Koff2 [min
-1
] (dilution + excess dopamine) 
F2,27 = 33.43 →  P < 0.0001 
0.42 ± 0.09 
0.03 ± 0.003 
 
41 
59 
 
Kobb1 [min
-1
] (in presence of 1.6 nM [
3
H]SB269,652)  
Kobb2 [min
-1
] (in presence of 1.6 nM [
3
H]SB269,652) 
F2,30 = 10.99 →  P = 0.0003 
0.55 ± 0.41 
0.04 ± 0.01 
 
24.2 
75.8 
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Table 4. pIC50 values of SB269,652 at several human GPCRs stably expressed in recombinant cell 
lines. 
 
Receptor Cell line Radioligand (concentration) pIC50 
Human adenosine A1 CHO [
3
H]DPCPX (1 nM) <5 
Human adenosine A2A HEK-293 [
3
H]CGS-21680 (6 nM) <5 
Human adrenergic α1A CHO [
3
H]Prazosin (0.3 nM) <5 
Human adrenergic α1B CHO [
3
H]Prazosin (0.3 nM) <5 
Human adrenergic α1D CHO [
3
H]Prazosin (0.2 nM) <5 
Human adrenergic α2A CHO [
3
H]RX821,002 (0.8 nM) <5 
Human adrenergic α2B CHO [
3
H]RX821,002 (4.0 nM) <5 
Human adrenergic α2C CHO [
3
H]-RX821,002 (0.6 nM) <5 
Human adrenergic β1 Sf9 [
3
H]CGP12,177 (0.15 nM) <5 
Human adrenergic β2 Sf9 [
3
H]CGP12,177 (0.15 nM) <5 
Human histamine H1 HEK-293 [
3
H]pyrilamine (1 nM) <5 
Human histamine H2 CHO [
125
I]APT (0.075 nM) <5 
Human serotonin 5HT1A CHO [
3
H]8-OH-DPAT (0.4 nM) 5.44 
Human serotonin 5HT1B CHO [
3
H]GR125,743 (1.0 nM) <5 
Human serotonin 5HT1D CHO [
3
H]GR125,743 (1.0 nM) <5 
Human serotonin 5HT2A CHO [
3
H]Ketanserin (0.5 nM) <5 
Human serotonin 5HT2B CHO [
3
H]Mesulergine (1.0 nM) <5 
Human serotonin 5HT2C CHO [
3
H]Mesulergine (1.0 nM) <5 
Human serotonin 5HT4 CHO [
3
H]GR113,808 (0.1 nM) <5 
Human serotonin 5HT5A HEK-293 [
3
H]LSD (1.0 nM) <5 
Human muscarinic M1 CHO [
3
H]Pirenzepine (2.0 nM) <5 
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Human muscarinic M2 CHO [
3
H]AF-DX 384 (2.0 nM) 6.67 
Human muscarinic M3 CHO [
3
H]4-DAMP (0.2 nM) 5.8 
Human muscarinic M4 CHO [
3
H]4-DAMP (0.2 nM) 7.22 
Human muscarinic M5 CHO [
3
H]4-DAMP (0.3 nM) 5.77 
Human dopamine D1 CHO [
3
H]SCH23,390 (0.3 nM) <5 
Human dopamine D2L CHO [
3
H]Spiperone (0.5 nM) 6.43 
Human dopamine D3 CHO [
3
H]Spiperone (0.5 nM) 8.63 
Human dopamine D4 CHO [
3
H]Spiperone (0.4 nM) <5 
Human dopamine D5 GH4 [
3
H]SCH23,390 (0.3 nM) <5 
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Figure legends 
Fig. 1. (A) saturation and (B, C and D) inhibition binding isotherms of [
3
H]SB269,652 to 
membranes form CHO-D3 cells. Concentrations of [
3
H]SB269,652 in saturation experiments 
ranged from 0.05 nM to 5.5 nM (from 2860 to 314600 dpm for sample), while its concentration in 
competition experiments was 1.6 nM (91520 dpm per sample). In the saturation experiment, at 5.5 
nM concentration of [
3
H]SB269,652, the total binding was 5419 dpm while nonspecific binding 
was 1244 dpm, and the amount of proteins added in each sample was ~15 μg. Competition curves 
were fitted by a non-linear regression according to models assuming a single (dashed line) or two 
(solid line) binding sites. Graphs are representative of a single experiment out of three, each 
performed in triplicate (bars represent the S.D. of each triplicate determination). Spec. and Unsp. 
refer to specific and unspecific binding in the absence and presence of 2 mM dopamine set at 100% 
and 0%, respectively.  
 
Fig. 2. Dissociation (A, B and C) and association (D) binding kinetics of [
3
H]SB269,652 to 
dopamine D3 receptor. For calculation of dissociation rate constants, 20 ml of membranes were 
preloaded with 5 nM [
3
H]SB269,652 for 2 h and then diluted 100 times in the absence or in the 
presence of 100 µM haloperidol or 2 mM dopamine. The apparent association-rate constant (Kobb) 
was calculated in the presence of 1.6 nM [
3
H]SB269,652. Data were fitted by a non-linear 
regression according to models assuming a monoexponential (dashed line) or biexponential (solid 
line) kinetics. Graphs are representative of a single experiment our of three, each performed in 
triplicate (bars represent the S.D. of each triplicate determination). 
 
Fig. 3. Saturation binding of [
3
H]SB269,652 to membranes from striatal synaptosomes of wild 
type and dopamine D3 receptor (D3–/–) knockout mice. Concentrations of [
3
H]SB269,652 in 
saturation experiments ranged from 0.038 to 3.08 nM (from 2174 to 176176 dpm per sample). At 
3.08 nM concentration of [
3
H]SB269,652, the total binding was 5828 dpm while nonspecific 
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binding was 5118 dpm, and the amount of proteins added in each sample was ~190 μg. Data were 
fitted by a non-linear regression according to models assuming a single population of binding sites. 
The graph is representative of a single experiment out of four, each performed in triplicate (bars 
represent the S.D. of each triplicate determination). 
 
Fig. 4. Influence of SB269,652 and SB277,011A upon quinpirole-induced inhibition of forskolin-
stimulated ACVI activity at dopamine D2 receptor and co-transfected dopamine D2/D3 
receptor. 
COS-7 cells were single transfected or co-transfected with dopamine D2 and D3 receptors together 
with ACVI. The amount of plasmids co-transfected in μg/dish were: a) D2/ACVI (0.5/1); b) 
D3/ACVI (2.5/1); c) D2/D3/ACVI (0.5/2.5/1). In a and b the amount of transfected plasmids was 
made up to 4 μg with empty pcDNA. In panel A, quinpirole inhibited forskolin stimulated ACVI 
only in dopamine D2 receptor and co-transfected dopamine D2/D3 receptor cells, while no effect 
was observed in dopamine D3 receptor transfected cells. In panel B, SB269,652 inhibited only 
moderately quinpirole-induced inhibition of forskolin-stimulated ACVI activity in dopamine D2 
receptor transfected cells, while it gained efficiency and potency in presence of dopamine D2 and 
dopamine D3 receptors. In panel C, SB277,011A completely inhibited quinpirole-induced inhibition of 
forskolin-stimulated ACVI activity in both cells transfected with dopamine D2 receptor and co-
transfected with dopamine D2 and D3 receptors. 
 
Fig. 5. Schematic representation of the binding of SB269,652 at dopamine D3 receptor 
monomers and dimers. SB269,652 is represented with its three main moities, the 7CN-THIQ 
group (blue), the transcyclohexylene spacer in the middle and the indole-2-carboxamide tail 
(yellow). In the upper left part of the schema, SB269,652 is shown to bind allosterically to a ligand 
pre-occupied monomer thus preventing the dissociation of the orthosteric ligand (dopamine; red) or, 
upper right part, to bind in a bitopic mode to the orthosteric (Orth) and allosteric (All 1) sites, and 
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competing with the orthosteric ligand in the monomer. Binding to the sole allosteric site in the pre-
occupied receptor monomer has probably very low affinity and is not detectable in radioligand 
binding, as demonstrated by the lack of [
3
H]SB269,652 binding of the dopamine D3D110A receptor 
mutant. Nevertheless, binding to the sole allosteric site in pre-occupied receptors can be inferred by 
our previous experiment with cold SB269,652, where we demonstrated that this compound 
decreases the dissociation speed of [
3
H]nemonapride from dopamine D3 receptor (Silvano et al., 
2010). This binding mode would be unfavourable respect to the bitopic binding mode, and it would 
occur only when the receptor is pre-occupied and at high concentrations of SB269,652. This would 
justify why we did not see any binding of [
3
H]SB269,652 to the D3D110A mutant. Furthermore, it 
is possible that this configuration could be stabilized by the 7CN-THIQ group engaging another 
allosteric site (All 2). In the lower part of the cartoon, SB269,652 is shown to bind in a bitopic 
mode to one protomer of the dopamine dimer, and to exert an allosteric effect across dimer on the 
orthosteric ligand bound to the other protomer (Lane et al., 2014). Since the negative allosteric 
effect between the two compounds localised on the two different protomers of the dimer is 
reciprocal, the orthosteric ligand would increase the dissociation of SB269,652 through the dimer. 
Recognition of a single population of binding sites by [
3
H]SB269,652 in saturation experiments and 
dissociation kinetics (when dissociation was started by dilution), together with comparable Bmax 
values of [
3
H]SB269,652 and [3H]nemonapride at dopamine D3 receptor, suggest that binding of 
SB269,652 to one protomer of a dimer would not alter the binding of other molecules of SB269,652 
to the other protomer. 
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